WO2011025344A3 - Attenuated salmonella mutants wherein adhesin of bovine pathogenic escherichia coli is transformed, and vaccine composition for preventing and treating bovine colibacillosis and salmonellosis comprising same - Google Patents

Attenuated salmonella mutants wherein adhesin of bovine pathogenic escherichia coli is transformed, and vaccine composition for preventing and treating bovine colibacillosis and salmonellosis comprising same Download PDF

Info

Publication number
WO2011025344A3
WO2011025344A3 PCT/KR2010/005895 KR2010005895W WO2011025344A3 WO 2011025344 A3 WO2011025344 A3 WO 2011025344A3 KR 2010005895 W KR2010005895 W KR 2010005895W WO 2011025344 A3 WO2011025344 A3 WO 2011025344A3
Authority
WO
WIPO (PCT)
Prior art keywords
bovine
salmonella mutants
present
escherichia coli
salmonella
Prior art date
Application number
PCT/KR2010/005895
Other languages
French (fr)
Korean (ko)
Other versions
WO2011025344A2 (en
Inventor
이존화
정구남
김은성
김삼웅
허진
Original Assignee
전북대학교 산학협력단
전라북도
주식회사 중앙백신연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 전북대학교 산학협력단, 전라북도, 주식회사 중앙백신연구소 filed Critical 전북대학교 산학협력단
Publication of WO2011025344A2 publication Critical patent/WO2011025344A2/en
Publication of WO2011025344A3 publication Critical patent/WO2011025344A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides Salmonella mutants which comprise an adhesin gene of bovine pathogenic Escherichia coli, and are transformed into attenuated Salmonella mutants wherein asd, lon and cpxR genes are deleted; and a vaccine composition for preventing and treating bovine Colibacillosis and Salmonellosis comprising the same. The Salmonella mutants of the present invention efficiently deliver an antigen derived from Escherichia coli into bovine mucosa lymphoid tissues and induce powerful mucosal immunity, and enable the production of the associated vaccine and mass innoculation. In addition, the Salmonella mutants of the present invention allow the innoculation cost and the side effects such as pain, inflammation or the like to be reduced. The production and storage of the Salmonella mutants of the present invention are easy and thus economical. Therefore, the Salmonella mutants of the present invention prevent infections by inducing immune responses against Salmonella and can be used as a polyvalent vaccine due to the inducement of immune responses against expressing exogenous antigens.
PCT/KR2010/005895 2009-08-31 2010-08-31 Attenuated salmonella mutants wherein adhesin of bovine pathogenic escherichia coli is transformed, and vaccine composition for preventing and treating bovine colibacillosis and salmonellosis comprising same WO2011025344A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090081430A KR101151004B1 (en) 2009-08-31 2009-08-31 Vaccine composition for protection and treatment against pathogenic Escherichia coli and Salmonella in cattle by administration of attenuated Salmonella expressing adhesin gene of pathogenic Escherichia coli and vaccination method thereof
KR10-2009-0081430 2009-08-31

Publications (2)

Publication Number Publication Date
WO2011025344A2 WO2011025344A2 (en) 2011-03-03
WO2011025344A3 true WO2011025344A3 (en) 2011-08-25

Family

ID=43628655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005895 WO2011025344A2 (en) 2009-08-31 2010-08-31 Attenuated salmonella mutants wherein adhesin of bovine pathogenic escherichia coli is transformed, and vaccine composition for preventing and treating bovine colibacillosis and salmonellosis comprising same

Country Status (2)

Country Link
KR (1) KR101151004B1 (en)
WO (1) WO2011025344A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101481789B1 (en) * 2011-05-17 2015-01-14 전북대학교산학협력단 Vaccine composition comprising attenuated and immunopotentiated mutant of Salmonella Enteritidis for preventing salmonellosis
KR101374649B1 (en) * 2011-07-22 2014-03-17 전북대학교산학협력단 Attenuated Salmonella mutants expressing virulence factors of pathogenic Escherichia coli in poultry and Vaccine composition comprising thereof and application for protection and treatment against pathogenic Escherichia coli and Salmonella in poultry
KR101371355B1 (en) 2012-03-29 2014-03-14 전북대학교산학협력단 Oral fowl typhoid vaccine using a live adjuvant system
KR101893827B1 (en) * 2016-01-04 2018-08-31 전북대학교 산학협력단 Vaccine composition for preventing or treating porcine proliferative enteritis and salmonellosis simultaneouly comprising attenuated Salmonella mutant as effective component
CN109797198A (en) * 2019-02-18 2019-05-24 扬州大学 A kind of genetic screening methodology of anti-sheep F17 coli-infection
CN112852698B (en) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 Construction method and application of Brucella A19 strain asd gene deletion strain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080082156A (en) * 2007-03-07 2008-09-11 전북대학교산학협력단 Salmonella mutants deleted lon gene and/or cpxr gene and live salmonella vaccines comprising thereof
US20080286310A1 (en) * 2004-10-26 2008-11-20 University Of Maryland Baltimore Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrhagic Escherichia Coli in Cattle

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101178415B1 (en) * 2009-08-27 2012-08-31 주식회사 중앙백신연구소 Attenuated Salmonella mutants transformed with adhesin gene of pathogenic Escherichia coli in pigs and Vaccine composition comprising thereof for protection and treatment against pathogenic Escherichia coli and Salmonella in pigs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286310A1 (en) * 2004-10-26 2008-11-20 University Of Maryland Baltimore Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrhagic Escherichia Coli in Cattle
KR20080082156A (en) * 2007-03-07 2008-09-11 전북대학교산학협력단 Salmonella mutants deleted lon gene and/or cpxr gene and live salmonella vaccines comprising thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUILLOBEL H. C. ET AL.: "Immunization against the colonization factor antigen I of enterotoxigenic Escherichia coli by administration of abivalent Salmonella typhimurium aroA strain", BRAZ J MED BIOL RES, vol. 31, no. 4, April 1998 (1998-04-01), pages 545 - 554 *
WARD, S. J. ET AL.: "Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A", INFECT IMMUN, vol. 67, no. 5, May 1999 (1999-05-01), pages 2145 - 2152 *

Also Published As

Publication number Publication date
KR20110023502A (en) 2011-03-08
WO2011025344A2 (en) 2011-03-03
KR101151004B1 (en) 2012-06-22

Similar Documents

Publication Publication Date Title
WO2011025344A3 (en) Attenuated salmonella mutants wherein adhesin of bovine pathogenic escherichia coli is transformed, and vaccine composition for preventing and treating bovine colibacillosis and salmonellosis comprising same
WO2011025310A3 (en) Attenuated salmonella variant strain resulting from the genetic transformation of adhesin from pathogenic pig escherichia coli and a vaccine composition comprising the same for preventing and treating pathogenic colibacillosis and salmonellosis in pigs
Hoggarth et al. Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa
CA2856891C (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
SI2566507T1 (en) Capsular gram-positive bacteria bioconjugate vaccines
TW201620927A (en) USPA2 protein constructs and uses thereof
JP2015501656A5 (en)
RU2017104529A (en) COMPOSITIONS OF NEISSERIA MENINGITIDIS AND WAYS OF THEIR APPLICATION
MX2014004359A (en) Recombinant human naglu protein and uses thereof.
EA035991B9 (en) Novel polysaccharide and uses thereof
Won et al. Improved lysis efficiency and immunogenicity of Salmonella ghosts mediated by co-expression of λ phage holin-endolysin and ɸX174 gene E
WO2010033798A3 (en) Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment
WO2011140595A3 (en) Immunostimulatory and vaccine compositions
MX2009006178A (en) Salmonella vaccine.
NZ591103A (en) Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
RU2017142932A (en) PHARMACEUTICAL AND FOOD COMPOSITIONS FOR INDUCING SATURATION AND EXTENSION OF STATUE IN NEEDS IN THIS SUBJECTS
Jiang et al. Molecular mechanisms underlying protection against H9N2 influenza virus challenge in mice by recombinant Lactobacillus plantarum with surface displayed HA2-LTB
WO2009058833A3 (en) Mycoplasma bovis vaccine
JP2015529677A5 (en)
WO2012009774A3 (en) Recombinant microorganisms, methods for preparing vaccine strains, antigens, and vector vaccine compositions of same, uses thereof, and related antibodies, diagnostic kit, and treatment and/or prophylactic methods
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
Hong et al. Identification of Vibrio anguillarum outer membrane vesicles related to immunostimulation in the Japanese flounder, Paralichthys olivaceus
TW200833709A (en) Archaeal polar lipid aggregates for administration to animals
WO2010083477A3 (en) Broad spectrum vaccine against non-typhoidal salmonella
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812357

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10812357

Country of ref document: EP

Kind code of ref document: A2